LCOR Mediates Interferon-Independent Tumor Immunogenicity and Responsiveness to Immune-Checkpoint Blockade in Triple-Negative Breast Cancer

Researchers showed that immune-checkpoint blockade (ICB) therapy selects for ligand-dependent corepressor (LCOR)low CSCs with reduced antigen processing/presentation machinery driving immune escape and ICB resistance in triple-negative breast cancer.